Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients

Pancreas
Drucy BorowitzFrederick T Murray

Abstract

Currently available pancreatic enzyme products are crude porcine products with few data available regarding their efficacy, safety, and manufacture. We conducted a phase 1 study of a novel pancreatic enzyme product, TheraCLEC-Total (TCT), a proprietary formulation of microbial-derived lipase, protease, and amylase, to determine its safety and preliminary efficacy in cystic fibrosis. We conducted an open-label, dose-ranging study in 23 subjects diagnosed with pancreatic insufficiency with cystic fibrosis. The subjects received TCT containing lipase dose of 100, 500, 1000, 2500, or 5000 USP U/kg per meal with each meal or snack for 3 days. The clinical and laboratory parameters and adverse events (AEs) were monitored. There were no serious AEs. Most AEs were mild, although gastrointestinal complaints were common. TCT increased the coefficient of fat and nitrogen absorption in all groups except in the low-dose group. At the other dosing levels, the mean coefficient of fat and nitrogen absorption increases were 19.1% +/- 24.9% and 17.8% +/- 13.6%, respectively, whereas the mean stool weight decreased by 517 +/- 362 g. TCT was well tolerated in this short-term exposure study. The preliminary efficacy data demonstrate lipase and prot...Continue Reading

Associated Clinical Trials

References

Jul 29, 1976·The New England Journal of Medicine·F B StapletonM A Linshaw
Jul 1, 1996·The Journal of Pediatrics·D A KawchakV A Stallings
May 1, 1997·The New England Journal of Medicine·S C FitzSimmonsA B Lowenfels
May 15, 1998·The Journal of Pediatrics·B J Rosenstein, G R Cutting
Aug 26, 1998·Journal of the Royal Society of Medicine·P DurieL Ellis
Apr 26, 2001·Biotechnology and Bioengineering·B ShenoyA L Margolin
Dec 11, 2002·JAMA : the Journal of the American Medical Association·R Brian HaynesAmit X Garg
Mar 10, 2004·Expert Opinion on Biological Therapy·Sujit K BasuAlexey L Margolin
Sep 3, 2004·The Journal of Pediatrics·Drucy BorowitzKerry Jarembek
Sep 1, 2005·Journal of Pediatric Gastroenterology and Nutrition·Drucy BorowitzJames Heubi

❮ Previous
Next ❯

Citations

Apr 7, 2007·Current Opinion in Clinical Nutrition and Metabolic Care·Daina KalninsPaul Pencharz
Sep 1, 2007·Current Opinion in Gastroenterology·Paul Georg Lankisch
Jul 30, 2011·Current Opinion in Pediatrics·Heather A Wier, Robert J Kuhn
Sep 11, 2012·Thorax·Steven M RoweBonnie W Ramsey
Jul 27, 2007·Proceedings of the American Thoracic Society·Christopher H Goss, Alexandra L Quittner
Jul 15, 2011·Clinical and Experimental Gastroenterology·Aaron FiekerMartine Armand
Aug 27, 2009·Therapeutics and Clinical Risk Management·Devi Mukkai KrishnamurtyDana K Andersen
Jan 24, 2012·Journal of Pediatric Gastroenterology and Nutrition·Drucy BorowitzUNKNOWN Liprotamase 767 Study Group
Oct 1, 2008·Expert Review of Respiratory Medicine·James E Heubi
Jul 3, 2007·Expert Opinion on Emerging Drugs·Pamela L Zeitlin
Jun 1, 2010·Best Practice & Research. Clinical Gastroenterology·E C M SikkensM J Bruno
Jun 5, 2007·Pharmacotherapy·Marcus FerroneJames S Scolapio
May 17, 2011·Vaccine·Shasta D McClenahanChristine Uhlenhaut
Aug 13, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Drucy BorowitzUNKNOWN Liprotamase 726 Study Group
Nov 13, 2019·Pediatric Pulmonology·Kimberly AltmanKaren Maguiness
Jan 1, 2007·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Drucy BorowitzFrederick T Murray

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Bruce C TrapnellSteven Caras
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Jamie L WooldridgeCandace Lee
© 2022 Meta ULC. All rights reserved